BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26052743)

  • 1. Ultraviolet A1 phototherapy beyond morphea: experience in 83 patients.
    Connolly KL; Griffith JL; McEvoy M; Lim HW
    Photodermatol Photoimmunol Photomed; 2015 Nov; 31(6):289-95. PubMed ID: 26052743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma.
    Su O; Onsun N; Onay HK; Erdemoglu Y; Ozkaya DB; Cebeci F; Somay A
    Int J Dermatol; 2011 Aug; 50(8):1006-13. PubMed ID: 21781079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study.
    Andres C; Kollmar A; Mempel M; Hein R; Ring J; Eberlein B
    Br J Dermatol; 2010 Feb; 162(2):445-7. PubMed ID: 19785603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis.
    Morita A; Kobayashi K; Isomura I; Tsuji T; Krutmann J
    J Am Acad Dermatol; 2000 Oct; 43(4):670-4. PubMed ID: 11004624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UV-A1 therapy for nephrogenic systemic fibrosis.
    Tran KT; Prather HB; Cockerell CJ; Jacobe H
    Arch Dermatol; 2009 Oct; 145(10):1170-4. PubMed ID: 19841406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultraviolet A1 phototherapy for treatment of acrosclerosis in systemic sclerosis: controlled study with half-side comparison analysis.
    Durand F; Staumont D; Bonnevalle A; Hachulla E; Hatron PY; Thomas P
    Photodermatol Photoimmunol Photomed; 2007 Dec; 23(6):215-21. PubMed ID: 17986056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medium-dose is more effective than low-dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20-MHz ultrasound assessment.
    Sator PG; Radakovic S; Schulmeister K; Hönigsmann H; Tanew A
    J Am Acad Dermatol; 2009 May; 60(5):786-91. PubMed ID: 19211170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ultraviolet-A1 (UVA1) phototherapy in lichen sclerosus et atrophicus].
    Kreuter A; von Kobyletzki G; Happe M; Herde M; Breuckmann F; Stücker M; Altmeyer P
    Hautarzt; 2001 Oct; 52(10):878-81. PubMed ID: 17690817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phototherapy for sclerosing skin conditions.
    Teske NM; Jacobe HT
    Clin Dermatol; 2016; 34(5):614-22. PubMed ID: 27638441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence of morphea after successful ultraviolet A1 phototherapy: A cohort study.
    Vasquez R; Jabbar A; Khan F; Buethe D; Ahn C; Jacobe H
    J Am Acad Dermatol; 2014 Mar; 70(3):481-8. PubMed ID: 24365168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose UVA₁ phototherapy for scleroderma: what benefit can we expect?
    Pereira N; Santiago F; Oliveira H; Figueiredo A
    J Eur Acad Dermatol Venereol; 2012 May; 26(5):619-26. PubMed ID: 21635565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis.
    Abeck D; Schmidt T; Fesq H; Strom K; Mempel M; Brockow K; Ring J
    J Am Acad Dermatol; 2000 Feb; 42(2 Pt 1):254-7. PubMed ID: 10642681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells.
    Camacho NR; Sánchez JE; Martin RF; González JR; Sánchez JL
    J Am Acad Dermatol; 2001 Nov; 45(5):697-9. PubMed ID: 11606918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulomatous slack skin responds to UVA1 phototherapy.
    Oberholzer PA; Cozzio A; Dummer R; French LE; Hofbauer GF
    Dermatology; 2009; 219(3):268-71. PubMed ID: 19546523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose UVA1 phototherapy for proximal and acral scleroderma in systemic sclerosis.
    Rose RF; Turner D; Goodfield MJ; Goulden V
    Photodermatol Photoimmunol Photomed; 2009 Jun; 25(3):153-5. PubMed ID: 19438995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultraviolet A1 phototherapy for the treatment of localized scleroderma.
    Furuhashi T; Torii K; Ikumi K; Kato H; Nishida E; Morita A
    J Dermatol; 2020 Jul; 47(7):792-795. PubMed ID: 32383187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin.
    Wetzig T; Sticherling M; Simon JC; Hegenbart U; Niederwieser D; Al-Ali HK
    Bone Marrow Transplant; 2005 Mar; 35(5):515-9. PubMed ID: 15665847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma.
    Kreuter A; Hyun J; Skrygan M; Sommer A; Tomi NS; Breuckmann F; Altmeyer P; Gambichler T
    Arch Dermatol Res; 2006 Nov; 298(6):265-72. PubMed ID: 17009056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma.
    Kreuter A; Hyun J; Stücker M; Sommer A; Altmeyer P; Gambichler T
    J Am Acad Dermatol; 2006 Mar; 54(3):440-7. PubMed ID: 16488295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis.
    Kreuter A; Breuckmann F; Uhle A; Brockmeyer N; Von Kobyletzki G; Freitag M; Stuecker M; Hoffmann K; Gambichler T; Altmeyer P
    J Am Acad Dermatol; 2004 May; 50(5):740-7. PubMed ID: 15097958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.